Funding to accelerate U.S., European and Middle East commercialization and collect clinical evidence for U.S. weight loss marketing indication

资金用于加速美国、欧洲和中东地区的商业化进程，并收集临床证据以支持在美国的减肥适应症市场推广。

GOSSELIES, Belgium

比利时戈斯利

,

，

July 16, 2026

2026年7月16日

/PRNewswire/ -- Endo Tools Therapeutics (ETT), developers of advanced endoscopic medical devices, today announced the closing of its Series C financing round, raising € 20 million (c. $ 23 million) to advance U.S., European and Middle East commercialization of the endomina® platform, including the recently FDA-cleared endomina® EZFuse system, and to collect the clinical evidence necessary for a U.S.

/美通社/ -- 高级内窥镜医疗设备开发商Endo Tools Therapeutics（ETT）今日宣布完成C轮融资，筹集资金2000万欧元（约合2300万美元），用于推进endomina®平台（包括近期获得美国食品药品监督管理局（FDA）批准的endomina® EZFuse系统）在美国、欧洲和中东地区的商业化，并收集在美国市场所需的临床证据。

weight loss marketing indication. This oversubscribed round has been led by seasoned Medical Device investors Capricorn Partners via their Capricorn Healthtech Fund II and is supported by MGFO as well as existing investors..

减肥营销适应症。本轮融资超额认购，由经验丰富的医疗器械投资者Capricorn Partners通过其Capricorn Healthtech Fund II领投，并得到MGFO及现有投资者的支持。

'This financing marks an important step in scaling ETT's presence in the U.S., European and Middle East markets,' said Alexandre Chau, CEO of Endo Tools Therapeutics. 'With the recent FDA clearance of the endomina® EZFuse system, we are introducing a next-generation solution designed to simplify workflow, improve efficiency, and enhance the physician experience.

“此次融资标志着ETT在扩大其在美国、欧洲和中东市场布局方面迈出了重要一步，”Endo Tools Therapeutics首席执行官Alexandre Chau表示。“随着endomina® EZFuse系统最近获得美国食品药品监督管理局（FDA）的批准，我们正推出一款旨在简化工作流程、提高效率并优化医师体验的新一代解决方案。”

This funding will allow us to build on that momentum, drive adoption, and continue to collect the data needed to support broader clinical applications.'.

这笔资金将使我们能够借助这一势头，推动应用普及，并继续收集支持更广泛临床应用所需的数据。

The endomina platform consists of a triangulation platform and suturing units that can be affixed to standard, tested endoscopes, creating a flexible therapeutic channel that moves independently. This enables physicians to perform suturing through a natural orifice—the mouth. Endomina remains the only system that can be assembled on the endoscope inside the stomach, offering greater working space and easier instrument access through the esophagus.

Endomina平台由一个三角定位平台和缝合单元组成，这些组件可以固定在经过标准测试的内窥镜上，形成一个独立移动的灵活治疗通道。这使得医生能够通过自然腔道——口腔进行缝合操作。Endomina仍然是唯一可以在胃内组装于内窥镜上的系统，提供更大的操作空间，并通过食道实现更便捷的器械进入。

It is designed to serve a significant population of patients with Class I and II obesity seeking a minimally invasive procedure as an alternative to chronic .

该方案旨在为大量寻求微创手术以替代慢性治疗的Ⅰ类和Ⅱ类肥胖患者提供服务。

GLP-1

胰高血糖素样肽-1

therapy or as part of a combined treatment approach.

治疗或作为联合治疗方法的一部分。

The newly cleared endomina® EZFuse system builds on this foundation with a more intuitive design and a single-movement suturing mechanism that streamlines workflow by eliminating unnecessary steps. Early procedural experience has demonstrated significantly faster suturing, allowing physicians to complete procedures more efficiently without changing their established technique.

新近获得许可的endomina® EZFuse系统在此基础上进一步优化，采用更直观的设计和单次动作缝合机制，通过消除不必要的步骤来简化工作流程。早期临床操作经验表明，该系统显著加快了缝合速度，使医生能够在不改变既定技术的情况下更高效地完成手术。

The system is designed to reduce operational burden, minimize user fatigue, and improve procedural consistency—helping hospitals and ambulatory surgery centers optimize resource utilization and expand procedural capacity..

该系统旨在减轻操作负担，减少用户疲劳，并提高程序的一致性——帮助医院和门诊手术中心优化资源利用并扩大手术能力。

Filip Pintelon, Investment Partner at Capricorn Partners, added: 'We are excited to support ETT at this pivotal stage, with the recent FDA clearance of the EZFuse system, combined with strong clinical experience and a clear strategy for U.S. expansion, the company is very well positioned to transform gastrointestinal care with minimally invasive endoscopic solutions to continue to improve patient care.'.

Capricorn Partners 的投资合伙人 Filip Pintelon 补充道：“我们很高兴在这一关键阶段支持 ETT。随着 EZFuse 系统最近获得美国食品药品监督管理局（FDA）的批准，加之其丰富的临床经验以及明确的美国市场扩张战略，该公司已处于有利地位，能够通过微创内镜解决方案变革胃肠道护理，从而持续改善患者照护。”

The market for advanced endoscopic suturing and tissue approximation is large and expanding. In the U.S., millions of patients remain untreated due to the invasiveness of surgery. Globally, demand for less invasive options is driving double-digit growth in the endoscopic suturing devices market. By enabling advanced procedures through a natural orifice, and now with a next-generation system designed for speed and efficiency, the endomina platform is positioned to capture a meaningful share of this multibillion-dollar opportunity..

先进内镜缝合与组织对合市场庞大且持续扩张。在美国，由于外科手术具有侵入性，数百万患者仍未得到治疗。在全球范围内，对微创方案的需求正推动内镜缝合设备市场实现两位数增长。通过自然腔道开展先进手术，并凭借新一代专为速度和效率设计的系统，endomina平台有望在这一价值数十亿美元的市场机遇中占据可观份额。

About Endo Tools Therapeutics

关于Endo Tools Therapeutics

Located in Gosselies, Belgium, Endo Tools Therapeutics S.A. (ETT) offers a portfolio of advanced, incisionless and minimally invasive endoscopic medical devices. The company's mission is to develop solutions that expand the range of gastrointestinal procedures that can be performed using standard gastroscopes.

Endo Tools Therapeutics S.A.（ETT）总部位于比利时戈瑟利，提供一系列先进的无切口、微创内窥镜医疗器械。公司的使命是开发能够扩大可使用标准胃镜进行的胃肠道手术范围的解决方案。

By developing minimally invasive treatment solutions, ETT aims to reduce complications and hospital length of stay, while improving patient comfort. In Europe and select Middle East countries, the devices are approved for use in endoscopic gastroplasty procedures for the treatment of obesity, with over 1,500 procedures performed, while in the U.S.

通过开发微创治疗方案，ETT旨在减少并发症和住院时间，同时提高患者的舒适度。在欧洲和部分中东国家，这些设备已获批用于肥胖症治疗的内窥镜胃成形术，已完成超过1,500例手术，而在美国

they are cleared for placement of sutures and approximation of soft tissue in the gastrointestinal tract..

他们已获准进行胃肠道缝合及软组织对合。

www.endotools.com

www.endotools.com

SOURCE Endo Tools Therapeutics (ETT)

来源：Endo Tools Therapeutics（ETT）

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示